18.91
前日終値:
$18.40
開ける:
$18.59
24時間の取引高:
707.75K
Relative Volume:
0.92
時価総額:
$1.38B
収益:
$9.98M
当期純損益:
$-154.08M
株価収益率:
-7.3295
EPS:
-2.58
ネットキャッシュフロー:
$-159.66M
1週間 パフォーマンス:
-9.22%
1か月 パフォーマンス:
+20.22%
6か月 パフォーマンス:
-28.56%
1年 パフォーマンス:
-55.20%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
CLDX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CLDX
Celldex Therapeutics Inc
|
18.91 | 1.38B | 9.98M | -154.08M | -159.66M | -2.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.82 | 130.98B | 11.10B | -988.90M | -978.00M | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 64.65B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
622.93 | 39.39B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.55 | 34.32B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
232.25 | 28.03B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-28 | 開始されました | Canaccord Genuity | Buy |
2025-03-20 | 開始されました | Morgan Stanley | Overweight |
2025-02-13 | 開始されました | UBS | Buy |
2024-10-07 | 開始されました | Citigroup | Buy |
2024-09-30 | 開始されました | Goldman | Neutral |
2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-06-18 | 開始されました | Stifel | Buy |
2024-06-11 | 開始されました | Wolfe Research | Outperform |
2023-12-20 | 開始されました | TD Cowen | Outperform |
2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2023-08-22 | 開始されました | Wells Fargo | Underweight |
2021-09-17 | 開始されました | Jefferies | Buy |
2021-09-10 | 開始されました | SVB Leerink | Outperform |
2021-07-22 | 開始されました | Guggenheim | Buy |
2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
2017-08-01 | 再開されました | H.C. Wainwright | Buy |
2016-11-07 | 開始されました | Aegis Capital | Buy |
2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
2016-03-01 | 開始されました | H.C. Wainwright | Buy |
2015-08-11 | 繰り返されました | Brean Capital | Buy |
2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
2015-08-11 | 繰り返されました | ROTH Capital | Buy |
2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
2014-11-17 | 繰り返されました | ROTH Capital | Buy |
2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX
Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus
New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan
Celldex: Q4 Earnings Snapshot - Barchart.com
Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics Inc’s results are impressive - uspostnews.com
The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com
Canaccord Initiates Coverage on Celldex (CLDX) with a Positive O - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Celldex Therapeutics Inc [CLDX] Records 200-Day SMA of $28.24 - knoxdaily.com
Regeneron Pharmaceuticals, Inc [REGN] Shares Rise 0.40 % on Wednesday - knoxdaily.com
How to interpret Celldex Therapeutics Inc (CLDX)’s stock chart patterns - uspostnews.com
Chronic Spontaneous Urticaria Market Set for Robust Growth From - openPR.com
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha
Commit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using Options - Nasdaq
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com
Vanguard Group Inc. Acquires 12,213 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia
Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Corebridge Financial Inc. Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Detailed In New Research Report - openPR.com
Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq
Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines
Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa
When (CLDX) Moves Investors should Listen - news.stocktradersdaily.com
Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com
Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews
Why Celldex Deserves Your Attention? - RTTNews
Charles Schwab Investment Management Inc. Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
7 Analysts Have This To Say About Celldex Therapeutics - Benzinga
Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq
MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView
Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - MarketScreener
Personalized Cancer Vaccines Market | Growth, Innovations & - openPR
Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $55.38 - The AM Reporter
Strategies for Managing Chronic Spontaneous Urticaria - Medscape
Celldex Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):